logo
Plus   Neg
Share
Email

AstraZeneca Reports Approval Of Roxadustat In China - Quick Facts

AstraZeneca plc (AZN.L,AZN) announced that its partner FibroGen China has now received formal marketing authorisation from the National Medical Products Administration for roxadustat, a new oral treatment for patients with anaemia caused by chronic kidney disease that are on dialysis. The medicine can be prescribed to patients who use haemodialysis or peritoneal dialysis. AstraZeneca and FibroGen expect to launch roxadustat in China during the second half of 2019.

AstraZeneca and FibroGen China are collaborating on the development and commercialisation of roxadustat in China. FibroGen China conducted the China Phase III clinical trials and submitted the New Drug Application for registration of roxadustat to the Chinese regulatory authorities.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
MillerCoors LLC has filed a lawsuit against Anheuser-Busch Companies LLC, part of Anheuser-Busch InBev, alleging that Anheuser-Busch's ad campaigns associating MillerCoors' products, Miller Lite and Coor Light, with corn syrup is "false and misleading." During the Super Bowl, ABInBev ran an advertising campaign that mocked Miller Lite and Coors Light use corn syrup in brewing. Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018.
Follow RTT